Minerva gastroenterologica e dietologica · 2009
Management of autoimmune liver disease.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Maggs J, Cullen S
Аннотация
The management of autoimmune liver disease can be very challenging. The presentation and natural history of these disorders is highly variable and can be asymptomatic, acute or chronic. Diagnosis requires the skilled interpretation of serological markers and histological changes and sometimes of biliary tract imaging. The major treatment options are immunosuppressive therapy (steroids and azathioprine) in autoimmune hepatitis (AIH) and ursodeoxycholic acid in cholestatic conditions although other treatments continue to be developed and tested. The complications of these diseases, in particular hepatocellular carcinoma and, in PSC, cholangiocarcinoma, remain difficult to monitor or prevent. Liver transplantation remains the only therapeutic option for end stage of liver disease and determining the optimum time for a patient to undergo this procedure requires a sophisticated judgment of the risks and benefits of the procedure as they pertain to an individual patient.
Предметные рубрики MeSH
AutoantibodiesAzathioprineBile Duct NeoplasmsBile Ducts, IntrahepaticCarcinoma, HepatocellularCholagogues and CholereticsCholangiocarcinomaClinical Trials as TopicDrug Therapy, CombinationEvidence-Based MedicineGlucocorticoidsHepatitis, AutoimmuneHumansImmunosuppressive AgentsLiver NeoplasmsLiver TransplantationPrognosisRandomized Controlled Trials as TopicRisk FactorsUrsodeoxycholic Acid